サノフィ対アムジェン紛争 オーストラリアの近況
この記事は最初に2024年8月13日に英語で公開されました 標題は、何年にもわたるもっとも重要な医薬品特許紛争の一つであり、世界中の関係者の注目を集めています。アムジェン(Amgen)のPCSK9抗体特許に関するこの特許訴訟は、機能的および構造的に定義されている抗体クレームの有効性を評価する際に主要な法管轄区域が採用する多様な手法を浮き彫りにしてきました。 米国において、アムジェンの特許クレームは、最高巡回裁判所により実施可能性の欠如を理由として無効の判決を受けました。
この記事は最初に2024年8月13日に英語で公開されました 標題は、何年にもわたるもっとも重要な医薬品特許紛争の一つであり、世界中の関係者の注目を集めています。アムジェン(Amgen)のPCSK9抗体特許に関するこの特許訴訟は、機能的および構造的に定義されている抗体クレームの有効性を評価する際に主要な法管轄区域が採用する多様な手法を浮き彫りにしてきました。 米国において、アムジェンの特許クレームは、最高巡回裁判所により実施可能性の欠如を理由として無効の判決を受けました。
Read More
Meet us at AusBiotech 2024
The annual AusBiotech conference is a key event to discuss pivotal issues and emerging topics facing the life sciences & biotech industry in Australia, attracting delegates from around the...
The annual AusBiotech conference is a key event to discuss pivotal issues and emerging topics facing the life sciences...
Read More
Sanofi v Amgen dispute: Australian update
It’s one of the most consequential pharmaceutical patent disputes in years, one that is being closely watched by practitioners around the world. The patent litigation concerning Amgen’s PCSK9 antibody...
It’s one of the most consequential pharmaceutical patent disputes in years, one that is being closely watched by practitioners...
Read More
Skinny labelling in the Australian context: an overview
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be protected by several different patent claim formats, including method of...
This article was first published in the 2023 Pharmaceutical Patent Review. Key takeaways In Australia, new indications for known pharmaceuticals may be...
Read More
Pharmaceutical patent term extension in Australia
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial importance, and in recent years have become of particular interest...
This article was first published in the 2023 Pharmaceutical Patent Review. Patent term extensions (PTEs) can be of great commercial...
Read More
Infringement of second medical use claims | Federal Court decision adds guidance
In pharmaceutical patent litigation, issues concerning infringement of method of treatment and Swiss-style claims covering new indications for known substances arise frequently. In this article, we discuss the recent...
In pharmaceutical patent litigation, issues concerning infringement of method of treatment and Swiss-style claims covering new indications for known...
Read More
The 2023 Pharmaceutical Patent Review
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023. The past year saw a number of important Federal Court...
Welcome to Spruson & Ferguson’s wrap-up of the most notable developments in pharmaceutical patent law in Australia in 2023....
Read More
ToolGen unsuccessful in landmark CRISPR patent appeal
The Federal Court of Australia has delivered judgement in Australia’s landmark CRISPR patent dispute, finding that none of the claims in ToolGen Inc.’s patent application for platform CRISPR technologies...
The Federal Court of Australia has delivered judgement in Australia’s landmark CRISPR patent dispute, finding that none of the...
Read More
No pay day for Commonwealth in Sanofi pharmaceutical damages claim
Background In the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal Court of Australia has upheld the trial judge’s decision that...
Background In the keenly awaited judgment in Commonwealth of Australia v Sanofi (formerly Sanofi-Aventis)  FCAFC 97, the Full Court of the Federal...
Read More